Fig. 7
From: EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells
Co-administration of EZH2 inhibitors with gefitinib suppressed growth of H1299 cells in vivo. a-b GSK343, DZNep, gefitinib, GSK343 plus gefitinib and DZNep plus gefitinib and PBS were respectively injected subcutaneously into nude mice (n = 10). Tumor volumes in mice were measured every 5 days. Results are presented as mean ± standard deviation. * P < 0.05, ** P < 0.01. c Immunohistochemistry was performed to detect EZH2, ki67 and caspase-3 in tumor sections of nude mice